Artivila Biopharma

Artivila Biopharma is a clinical-stage biotechnology company that leverages an integrated artificial intelligence-driven drug discovery (AIDD) and computer-aided drug design (CADD) platform to develop small molecule therapeutics. Founded in 2018 and headquartered in Shenzhen, China, the company focuses on therapeutic areas with high unmet needs, including autoimmune diseases, neurodegenerative disorders, and oncology. Its proprietary "eLEAD" platform combines AI algorithms with human expertise (AI+HI) to accelerate research and development and improve clinical success rates. The company's lead candidate, ARD-885, is a dual-target inhibitor of IRAK1 and IRAK4 that recently completed Phase 1 clinical trials for the treatment of rheumatoid arthritis. Artivila maintains a robust pipeline of first-in-class and best-in-class programs aimed at translating scientific breakthroughs into accessible medicines.